Lupin has launched authorized generic version of Horizon Therapeutics PLC's Vimovo (naproxen/esomeprazole magnesium) delayed release tablets, 375 mg/20 mg and 500 mg/20 mg in the US.
The product is a combination of naproxen, a non-steroidal anti-inflammatory drug (NSAID), and esomeprazole magnesium, a proton pump inhibitor (PPI) indicated in adult and adolescent patients 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers.
Naproxen and Esomeprazole Magnesium delayed-release tablets (RLD: Vimovo) had an annual sales of approximately $400 million in the US.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
